Citations

Clear

7552 citation(s) found for "Ku, Matthew".

Outcomes of Relapsed or Refractory Diffuse Large B‐Cell Lymphoma Treated With R‐ GemOx : A Multicenter Cohort Study
Yamshon, Samuel , Koff, Jean L. , Larson, Melissa C. , Kahl, Brad S. , Casulo, Carla , Lossos, Izidore S. , Haddadi, Sara , Stanchina, Michele , Chihara, Dai , Ayers, Amy , Khurana, Arushi , Nowakowski, Grzegorz S. , Reicks, Tanner W., Cohen, Jonathon B. , Martin, Peter , Li, Jia , Shewade, Ashwini, Batlevi, Connie Lee , Lo‐Rossi, Andrea, Fox, David , Masaquel, Anthony, Mun, Yong, Flowers, Christopher R. , Habermann, Thomas , Wang, Yucai , Khurana, Arushi , Nowakowski, Grzegorz S , Farooq, Umar , Link, Brian K , Cohen, Jonathon B , Li, Jia , Shewade, Ashwini , Batlevi, Connie L , Lo-Rossi, Andrea , Fox, David , Masaquel, Anthony , Cerhan, James R , Maurer, Matthew , Kahl, Brad S , Koff, Jean L , Chihara, Dai , Casulo, Carla , Larson, Melissa C , Habermann, Thomas M. , Wang, Yucai , Link, Brian K. , Cerhan, James R. , Maurer, Matthew J. , Nastoupil, Loretta J.

Mayo Clinic

American Journal of Hematology | February 7, 2025 | Volume: 100 | Issue: 4 | Pages: 606-615

10.1002/ajh.27630 | PMID 39918101 Get It

ABSTRACT Rituximab, gemcitabine, and oxaliplatin (R‐GemOx) is a commonly used chemoimmunotherapy regimen for relapsed or refractory (R/R) diffuse large B‐cell lymphoma (DLBCL), but there are limited real‐world data. In a multicenter retrospective study from a cohort of eight US academic centers (LEO CReWE), we evaluated 183 patients with R/R DLBCL and high‐grade B cell lymphoma treated with R‐GemOx, including subgroups treated without intent for consolidation with autologous stem cell transplant (ASCT) or chimeric antigen receptor (CAR) T cell therapy ( n = 100), those utilizing R‐GemOx as a bridge to ASCT or CAR T ( n = 83), and those aged 70 and older ( n = 71). Overall response rates (ORRs) for all patients treated with R‐GemOx were 45% with a complete response (CR) rate of 29%. The median event‐free survival (EFS) was 2.3 months, and the median overall survival (OS) was 13.5 months. Patients receiving R‐GemOx without intent for ASCT or CAR T had ORR and CR rates of 33% and 18%, respectively, with median EFS and OS of 2.0 and 9.5 months, respectively. Patients receiving R‐GemOx as a bridge to ASCT or CAR T had ORR and CR rates of 57% and 36%, respectively, with median EFS and OS of 3.5 and 17.4 months, respectively. Patients receiving R‐GemOx aged 70 and older had ORR and CR rates of 53% and 33%, respectively, with median EFS and OS of 2.2 and 13.9 months, respectively. These data provide a benchmark for R‐GemOx in the rapidly evolving landscape of R/R DLBCL therapies.
Efficacy and safety of preoperative embolization in surgical treatment of brain arteriovenous malformations: a multicentre study with propensity score matching
Salim, Hamza , Hamdan, Dawoud, Adeeb, Nimer , Aslan, Assala , Musmar, Basel , Ogilvy, Christopher S. , Dmytriw, Adam A. , Ataoglu, Cagdas , Erginoğlu, Ufuk , Naamani, Kareem El, Sheehan, Jason P. , Ironside, Natasha , Gummadi, Sanjeev, Keleş, Abdullah , Muram, Sandeep , Sconzo, Daniel , Rezai, Arwin, Alwakaa, Omar , Sen, Rajeev , Başkaya, Mustafa K. , Tjoumakaris, Stavropoula , Atallah, Elias , Riina, Howard A. , Abushehab, Abdallah, Swaid, Christian, Burkhardt, Jan‐Karl , Starke, Robert M., Altschul, David , Haranhalli, Neil , McAvoy, Malia , Abla, Adib A. , Stapleton, Christopher J. , Koch, Matthew J. , Srinivasan, Visish M. , Cochran, Joseph, Pukenas, Bryan , Smith, Edward R. , Moehlenbruch, Markus, Alaraj, Ali , Patel, Aman B. , Yedavalli, Vivek , Cuellar, Hugo H, Lawton, Michael T. , Guthikonda, Bharat , Aslan, Assala , Musmar, Basel , Ogilvy, Christopher S , Dmytriw, Adam A , Essibayi, Muhammed Amir , Alwakaa, Omar , Griessenauer, Christoph J , Jabbour, Pascal , Altschul, David J , Koch, Matthew J , Chen, Peng R , Orbach, Darren B , Alaraj, Ali , Yedavalli, Vivek S , Abla, Adib , Salim, Hamza , Keles, Abdullah , Erginoglu, Ufuk , Smith, Edward , Hamdan, Dawoud , Kandregula, Sandeep , Abdelsalam, Ahmed , Kondziolka, Douglas , Naamani, Kareem El , Kumbhare, Deepak , Essibayi, Muhammed Amir , Tos, Salem M , Rezai, Arwin, Pöppe, Johannes , Sen, Rajeev D, Griessenauer, Christoph J. , Jabbour, Pascal , Sekhar, Laligam N. , Levitt, Michael R. , Blackburn, Spiros , Choudhri, Omar , Orbach, Darren B. , Mosimann, Pascal J , Aziz‐Sultan, Mohammad Ali , Wintermark, Max , Savardekar, Amey Rajan , Morcos, Jacques J.

Mayo Clinic

Journal of Neurology, Neurosurgery & Psychiatry | February 6, 2025 | Volume: 96 | Issue: 8 | Pages: 766-774

10.1136/jnnp-2024-334974 | PMID 39915091 Get It

Background Brain arteriovenous malformations (AVMs) are abnormal connections between feeding arteries and draining veins, associated with significant risks of haemorrhage, seizures and other neurological deficits. Preoperative embolization is commonly used as an adjunct to microsurgical resection, with the aim of reducing intraoperative complications and improving outcomes. However, the efficacy and safety of this approach remain controversial. Methods This study is a subanalysis of the Multicenter International Study for Treatment of Brain AVMs consortium. We retrospectively analysed 486 patients with brain AVMs treated with microsurgical resection between January 2010 and December 2023. Patients were divided into two groups: those who underwent microsurgery alone (n=245) and those who received preoperative embolization, followed by microsurgery (n=241). Propensity score matching was employed, resulting in 288 matched patients (144 in each group). The primary outcomes were rates of complete AVM obliteration and functional outcomes (measured by the modified Rankin Scale (mRS)). Secondary outcomes included complication rates, mortality, hospital length of stay and postsurgical rupture. Results After matching, the complete obliteration rate was 97% with no significant difference between the microsurgery-only group and the preoperative embolization group (p=0.12). The proportion of patients with an mRS score of 0–2 at the last follow-up was similar in both groups (83% vs 84%; p=0.67). The median hospital stay was significantly longer for the embolisation group (9 days vs 7 days; p=0.017). Complication rates (24% vs 22%; p=0.57) and mortality rates (4.9% vs 2.1%; p=0.20) were comparable between the two groups. No significant differences were observed in postsurgical rupture, recurrence or retreatment rates. Conclusions In this large multicentre study, preoperative embolization did not significantly improve AVM obliteration rates, functional outcomes or reduce complications compared with microsurgery alone.
Heterochromatin fidelity is a therapeutic vulnerability in lymphoma and other human cancers
Najia, Mohamad , Jha, Deepak Kumar , Zhang, Cheng , Kubaczka, Caroline , Markel, Arianna , Li, Christopher , Morris, Vivian Gunn, Tompkins, Allison, Hensch, Luca, Qin, Yue , Huang, Yu-Chung , Marunde, Matthew R. , Vaidya, Anup , Gillespie, Zachary B , Shi, Yang , Li, Hu , Daley, George Q. , Najia, Mohamad Ali , Jha, Deepak K , North, Trista E , Keogh, Michael-Christopher , Schlaeger, Thorsten M , Shipp, Margaret Ann , Blainey, Paul C , Daley, George Q , Laurent, Benoît , Li, Christopher, Morris, Vivian, Chapuy, Bjoern , Morse, Michael, Howard, Sarah A. , Domínguez, Daniel

Mayo Clinic

No container title available | February 5, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.01.31.635709 | PMID 39975048 Get It

ABSTRACT Genes involved in the regulation of chromatin structure are frequently disrupted in cancer, contributing to an aberrant transcriptome and phenotypic plasticity. Yet, therapeutics targeting mutant forms of chromatin-modifying enzymes have yielded only modest clinical utility, underscoring the difficulty of targeting the epigenomic underpinnings of aberrant gene regulatory networks. Here, we sought to identify novel epigenetic vulnerabilities in diffuse large B-cell lymphoma (DLBCL). Through phenotypic screens and biochemical analysis, we demonstrated that inhibition of the H3K9 demethylases KDM4A and KDM4C elicits potent, subtype-agnostic cytotoxicity by antagonizing transcriptional networks associated with B-cell identity and epigenetically rewiring heterochromatin. KDM4 demethylases associated with the KRAB zinc finger ZNF587, and their enzymatic inhibition led to DNA replication stress and DNA damage-induced cGAS-STING activation. Broad surveys of transcriptional data from patients also revealed KDM4 family dysregulation in several other cancer types. To explore this potential therapeutic avenue, we performed high-throughput small molecule screens with H3K9me3 nucleosome substrates and identified novel KDM4 demethylase inhibitors. AI-guided protein-ligand binding predictions suggested diverse modes of action for various small molecule hits. Our findings underscore the relevance of targeting fundamental transcriptional and epigenetic mechanisms for anti-cancer therapy. HIGHLIGHTS Phenotypic screens identified JIB-04 as a potent anti-cancer agent for multiple subtypes of diffuse large B-cell lymphoma JIB-04 binds and inhibits KDM4 demethylases resulting in epigenomic rewiring of heterochromatin KDM4 demethylases cooperate with KRAB zinc fingers to limit DNA replication stress, and KDM4 inhibition instigates DNA-damage and cGAS-STING activation in several human cancers High-throughput small molecule screens with semi-synthetic nucleosome substrates and AI-guided molecular docking simulations identify novel KDM4 inhibitors
Trends in Outpatient Radical Prostatectomy and Same-Day Discharge for Prostate Cancer: Analysis of the National Inpatient Sample and Nationwide Ambulatory Surgery Sample
Henning, Grant , Deol, Ekamjit S. , Tollefson, Matthew K. , Frank, Igor, Shah, Paras , Khanna, Abhinav, Karnes, R. Jeffrey , Boorjian, Stephen A. , Sharma, Vidit , Henning, Grant M , Vasdev, Ranveer M, Basourakos, Spyridon P. , Yang, David Y. , Vasdev, Ranveer

Mayo Clinic

Urology Practice | February 4, 2025 | Volume: 12 | Issue: 3 | Pages: 305-315

10.1097/upj.0000000000000778 | PMID 39903835 Get It

Here's to a Future Beyond Reconstructive Surgery for Pelvic Osteomyelitis
Zein, Said El , Melin, Matthew M , Tran, Nho V. , Rose, Peter S. , Berbari, Elie F. , El Zein, Said , Suh, Gina A.

Mayo Clinic

Clinical Infectious Diseases | February 4, 2025 | Volume: 81 | Issue: 2 | Pages: e36-e36

10.1093/cid/ciaf051 | PMID 39903550 Get It

Real‐world clinical experience with serum MOG and AQP4 antibody testing by live versus fixed cell‐based assay
Said, Yana , Filippatou, Angeliki , Tran, Conlan , Rezavi, LuAnn, Guo, Kai , Resto, Yasmin, Chen, John J. , Pittock, Sean J. , Sotirchos, Elias S. , Pittock, S J , Calabresi, Peter A , Sotirchos, Elias S , Chen, John J , Said, Yana , Filippatou, Angeliki G , Smith, Matthew D. , Calabresi, Peter A. , Caturegli, Patrizio , Flanagan, Eoin P.

Mayo Clinic

Annals of Clinical and Translational Neurology | February 4, 2025 | Volume: 12 | Issue: 3 | Pages: 556-564

10.1002/acn3.52310 | PMID 39901660 Get It

Abstract Objective To assess the real‐world performance of a live (LCBA) versus a fixed (FCBA) cell‐based assay for the detection of serum antibodies directed against myelin oligodendrocyte glycoprotein (MOG‐IgG) and aquaporin‐4 (AQP4‐IgG). Methods This was a retrospective study of patients evaluated at a single tertiary academic referral center, with serum testing performed clinically for AQP4‐IgG and/or MOG‐IgG by FCBA and LCBA on the same day. Additionally, frozen banked sera from the same day for patients tested only by one assay were retrieved and tested by the other assay. FCBA was performed by the Johns Hopkins Immunology Laboratory using Euroimmun kits with detection by indirect immunofluorescence (FCBA‐IF), whereas LCBA was performed by the Mayo Clinic Neuroimmunology Laboratory with detection by flow cytometry (LCBA‐FACS). Results Of 594 specimens with paired MOG‐IgG testing, 500 were negative by both assays, 33 were positive by both assays, 56 were positive exclusively by LCBA‐FACS, and 5 were only positive by FCBA‐IF. Overall, MOG‐IgG LCBA‐FACS exhibited 95.1% sensitivity and 97.7% specificity, whereas MOG‐IgG FCBA‐IF had 45.7% sensitivity and 99.8% specificity. Of 577 specimens with paired AQP4‐IgG testing, 503 were negative by both assays, 51 were positive by both assays, 21 were positive exclusively by LCBA‐FACS, and 2 were only positive by FCBA‐IF. Overall, AQP4‐IgG LCBA‐FACS exhibited 97.3% sensitivity and 100% specificity, whereas AQP4‐IgG FCBA‐IF had 71.6% sensitivity and 100% specificity. Interpretation LCBA‐FACS for both MOG‐IgG and AQP4‐IgG had markedly better sensitivity than FCBA‐IF, with similar specificity. The use of FCBA‐IF may result in underrecognition of both MOG antibody‐associated disease (MOGAD) and AQP4‐IgG seropositive neuromyelitis optica spectrum disorder (NMOSD).
Atf4 protects islet β-cell identity and function under acute glucose-induced stress but promotes β-cell failure in the presence of free fatty acid
Yagan, Mahircan, Najam, Sadia, Hu, Ruiying, Dickerson, Mathew, Dadi, Prasanna K. , Xu, Yanwen , Stein, Roland , Jacobson, David A. , Gu, Guoqiang , Stein, Roland , Gu, Guoqiang , Najam, Sadia, Wang, Yu , Dickerson, Matthew T. , Simmons, Alan J. , Adams, Christopher M. , Lau, Ken S. , Liu, Qi

Mayo Clinic

Diabetes | February 3, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.2337/db24-0360 | PMID 39899446 Get It

Glucolipotoxicity, caused by combined hyperglycemia and hyperlipidemia, results in β-cell failure and type 2 diabetes via cellular stress-related mechanisms. Activating transcription factor 4 (Atf4) is an essential effector of stress response. We show here that Atf4 expression in β-cells is minimally required for glucose homeostasis in juvenile and adolescent mice but it is needed for β-cell function during aging and under obesity-related metabolic stress. Henceforth, Atf4-deficient β-cells older than 2 months after birth display compromised secretory function under acute hyperglycemia. In contrast, they are resistant to acute free fatty acid-induced dysfunction and reduced production of several factors essential for β-cell identity. Atf4-deficient β-cells down-regulate genes involved in protein translation. They also upregulate several lipid metabolism or signaling genes, likely contributing to their resistance to free fatty acid-induced dysfunction. These results suggest that Atf4 activation is required for β-cell identity and function under high glucose. But Atf4 activation paradoxically induces β-cell failure in high levels of free fatty acids. Different transcriptional targets of Atf4 could be manipulated to protect β-cells from metabolic stress-induced failure.
Aerosol Generation During Spirometry and Simulated Bronchodilator Challenge Testing in the Pulmonary Function Laboratory
Gmehlin, Cameron G., Sajgalik, Pavol , Hainy, Matthew E, Kim, Chul‐Ho , Johnson, Bruce D. , Allison, Thomas G. , Gmehlin, Cameron G. , Lim, Kaiser, Lim, Kaiser G. , Niven, Alexander S.

Mayo Clinic

Respiratory Care | February 3, 2025 | Volume: 70 | Issue: 4 | Pages: 446-449

10.1089/respcare.12506 | PMID 39969939 Get It

Valve thrombosis and antithrombotic therapy after bioprosthetic mitral valve replacement: a systematic review and meta-analysis
Zorman, Mark , Vibhishanan, Jonathan , Dangas, Katerina, Castle, James , Li, Ka Hou Christien , Coronelli, Marco , Eastwick-Jones, Kate , Swan, Alexander, Johnson, N M, Choksey, Anurag , Scott, Sam G.C., Henry, Matthew , Cassar, Mark Philip , Barnes, C. , Ferreira‐Martins, João , Newton, James D. , Alkhouli, Mohamad , Rihal, Charanjit S. , Eleid, Mackram F. , Zorman, Mark J , Newton, James , Dawkins, Sam , Rihal, Charanjit, Eleid, Mackram F , Sabbah, Michael S. , Swan, Alexander, Johnson, Nicky, Yan, Helen H.N. , Barnes, Cara, Alkhouli, Mohamad , Rihal, Charanjit S. , Pislaru, Sorin V. , Guerrero, Mayra , Ordóñez-Mena, José Manuel , Cahill, Thomas J.

Mayo Clinic

European Heart Journal - Cardiovascular Pharmacotherapy | February 2, 2025 | Volume: 11 | Issue: 3 | Pages: 251-263

10.1093/ehjcvp/pvaf005 | PMID 39904549 Get It

Abstract Aims Transcatheter mitral valve replacement (TMVR) has become a feasible alternative to surgical mitral valve replacement (SMVR) in selected patients at high surgical risk. The risk of valve thrombosis following SMVR and TMVR, and the optimal antithrombotic therapy following these procedures, remains uncertain. We aimed to compare the incidence of bioprosthetic mitral valve thrombosis (bMVT) after SMVR and TMVR, and the incidence of bMVT between patients on different antithrombotic regimens. Methods and results A literature search of Medline, Embase, and Cochrane Library was performed between January 2000 and August 2024. Random-effects models were used to derive pooled estimates of the incidence of bMVT in the absence of prior or active endocarditis and valve thrombosis. A total of 47 studies (6170 patients, total follow-up 9541.8 patient-years) were eligible for inclusion. The overall incidence of bMVT was 5.05 [95% confidence interval (CI) 3.18–8.01, I2 = 82%] per 100-patient-years. Subclinical bMVT was more common than clinically significant bMVT: incidence 19.11 vs. 7.91 per 100-patient-years, adjusted incidence rate ratio (aIRR) 4.62 (95% CI 1.39–15.36), P = 0.012. bMVT was numerically more common after TMVR than SMVR, but the comparison was not statistically significant: incidence 7.03 vs. 0.58 per 100-patient-years, aIRR 2.19 (95% CI 0.72–6.72), P = 0.170. Patients on vitamin-K antagonists (VKA) had a lower incidence of bMVT than patients on direct oral anticoagulants (DOAC; incidence 5.72 vs. 17.08, aIRR 0.31, 95% CI 0.13–0.73, P = 0.007). Conclusions bMVT is not uncommon, with numerically higher incidence in transcatheter compared to surgical valves, but the comparison was not statistically significant. VKAs are associated with a lower incidence of bMVT compared to DOACs.
Identifying consensus and areas for future research in chondrosarcoma
Kurisunkal, Vineet , Botello, Eduardo , Boyle, Richard A. , Ebeid, Walid , Houdek, Matthew T. , Puri, Ajay , Brennan, Bernadette , Laitinen, Minna , Jutte, Paul C. , Lazarides, Alexander L. , Verspoor, F.G.M. , Visgauss, Julia D. , Jeys, Lee M , Morris, Guy V , Kurisunkal, Vineet , Botello, Eduardo , Ebeid, Walid , Houdek, Matthew T , Puri, Ajay , Ruggieri, Pietro , Brennan, Bernadette , Laitinen, Minna K , Couch, Cory , Rose, Peter, Sullivan, Mikaela, Tibbo, Meagan, Jutte, Paul , Visgauss, Julia D , Jeys, Lee , Ruggieri, Pietro

Mayo Clinic

The Bone & Joint Journal | February 1, 2025 | Volume: 107-B | Issue: 2 | Pages: 246-252

10.1302/0301-620x.107b2.bjj-2024-0643.r1 | PMID 39889743 Get It

AimsThe Birmingham Orthopaedic Oncology Meeting (BOOM), held in January 2024, convened 309 delegates from 53 countries to discuss and refine 21 consensus statements on the optimal management of chondrosarcoma.MethodsWith representation from Europe (43%; n = 133), North America (17%; n = 53), South America (16%; n = 49), Asia (13%; n = 40), Australasia (5%; n = 16), the Middle East (4%; n = 12), and Africa (2%; n = 6), the combined experience of treating bone sarcomas among attendees totalled approximately 30,000 cases annually, equivalent to 66 years of experience in the UK alone. The meeting’s process began with the formation of a local organizing committee, regional leads, and a scientific committee comprising representatives from 150 specialist units across 47 countries. Supported by major orthopaedic oncology organizations, the meeting used a modified Delphi process to develop consensus statements through online questionnaires, thematic groupings, narrative reviews, and anonymous pre-meeting polling.ResultsStrong (> 80%) consensus was achieved on 19 out of 21 statements, reflecting agreement among delegates. Key areas of consensus included the role of radiology in diagnosis and surveillance, the management of locally recurrent disease, and the treatment of dedifferentiated chondrosarcoma. Notably, there was agreement that routine chemotherapy has no role in chondrosarcoma treatment, and radiological surveillance is safe for intraosseous chondrosarcomas. Despite the overall consensus, areas of controversy remain, particularly regarding the treatment of atypical cartilage tumours and surgical margins. These unresolved issues underscore the need for further research and collaboration within the orthopaedic oncology community.ConclusionBOOM represents the largest global consensus meeting in orthopaedic oncology, providing valuable guidance for clinicians managing chondrosarcoma worldwide. The consensus statements offer a reference for clinical practice, highlight key research priorities, and aim to improve patient outcomes on a global scale.Cite this article: Bone Joint J 2025;107-B(2):246–252.